Related Experiment Video

Updated: Jun 2, 2026

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

Transforming growth factor-β adaptor, β2-spectrin, modulates cyclin dependent kinase 4 to reduce development of

Hye Jung Baek1, Michael J Pishvaian, Yi Tang

  • 1Radiation Medicine Branch, National Cancer Center, Goyang, Korea.

Hepatology (Baltimore, Md.)
|April 27, 2011
PubMed
Abstract

Insights

Beta-2 spectrin (β2SP) deficiency activates cyclin dependent kinase 4 (CDK4), promoting cell cycle dysregulation and hepatocellular carcinoma (HCC) formation. Targeting CDK4 may offer a new therapeutic strategy for HCC.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Transforming growth factor beta (TGF-β) signaling loss is crucial in cancer development.
  • Beta-2 spectrin (β2SP) modulates TGF-β tumor suppressor functions and is implicated in tumorigenesis.
  • The precise role of TGF-β signaling in hepatocellular carcinoma (HCC) progression, especially concerning other oncogenic pathways, is not fully understood.

Purpose of the Study:

  • To elucidate the mechanism by which β2SP regulates cell cycle progression and suppresses HCC.
  • To investigate the interplay between β2SP, Smad3, and cyclin dependent kinase 4 (CDK4) in HCC development.

Main Methods:

  • Investigated the effect of β2SP on retinoblastoma gene product (Rb) phosphorylation and CDK4 expression.
  • Examined the interaction between β2SP, CDK4, and Smad3 in a TGF-β-dependent manner.
  • Utilized β2SP haploinsufficient (β2sp(+/-)) and cdk4 haploinsufficient mice to assess HCC formation.

Main Results:

  • Increased β2SP expression inhibited Rb phosphorylation and reduced CDK4 expression, leading to G1 cell cycle arrest.
  • β2SP competitively interacted with CDK4 and Smad3 in a TGF-β-dependent manner.
  • Haploinsufficiency of cdk4 significantly reduced HCC formation in β2sp(+/-) mice.

Conclusions:

  • β2SP deficiency activates CDK4, disrupting cell cycle control, promoting proliferation, and driving HCC formation.
  • CDK4 is identified as a potential therapeutic target for HCC treatment.
  • The β2sp(+/-) mouse model is valuable for preclinical evaluation of HCC therapies.

More Related Videos

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Spheroid Assay to Measure TGF-β-induced Invasion09:18

Spheroid Assay to Measure TGF-β-induced Invasion

Published on: November 16, 2011

Related Concept Videos

TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.